T = Trends for a Stock’s Movement
Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The company consists of four operating segments: the Pharmaceutical, Animal Health, Consumer Care, and Alliances segments, and one reportable segment in the Pharmaceutical segment. Merck aims to provide valuable healthcare products and services to consumers, animals, and companies in need worldwide. Look for the company to see rising profits as it advances the products and services of the healthcare field.
Merck research Chief Roger Perlmutter has stated that the company is more than open to the idea of buying big acquisitions of biotech companies rather than go forward and obtain drug development technologies. Mr. Perlmutter reiterated the company’s attitude for new deals at the back of the planned $3.85 billion acquisition of Idenix Pharmaceuticals (NASDAQ:IDIX). Merck has already announced its plans to buy Idenix and planning to combine the two company’s oral drugs for hepatitis C, with a view of producing a faster cure for the fatal liver infection that currently affects more than 170 million people worldwide. This is part of Merck’s efforts to be a pioneer in the development of Hepatitis C drugs. Mr. Roger also maintains that newer drugs are hoped at tripling therapy using Idenix’s IDX21437 sure to make Merck a top competitor in the Hepatitis C spectrum. Merck’s $3.85 billion acquisition of Idenix essentially gives it additional experimental medicines. Idenix Pharmaceuticals is reported to be developing a medicine class called ‘nucs,’ a valuable part in new treatment regimens.